Combining acid ceramidase and Bcl-2 inhibition to treat acute myeloid leukemia
Official title: Mechanisms and In Vivo Efficacy of Synergistic Acid Ceramidase and Bcl-2 Inhibition in Acute Myeloid Leukemia
Funded at University of Virginia · NIH-11179104 · Data updated 2026-11-12
This study is looking at a new way to treat acute myeloid leukemia (AML) by using a combination of two medications to see if they can work better together, especially for patients who can’t handle regular chemotherapy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Virginia NIH-funded |
| Lab location | 1 site (Charlottesville, United States) |
| Project start | August 10, 2023 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $38,061 |
| NIH project number | 5F99CA284252-02 |
| Project ID | NIH-11179104 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with acute myeloid leukemia who are unable to tolerate standard induction chemotherapy.
✕Less likely to help
Patients with other types of leukemia or those who have already received extensive treatment may not benefit from this research.
What this research studies
This research investigates a new treatment approach for acute myeloid leukemia (AML) by combining an acid ceramidase inhibitor with venetoclax, a Bcl-2 antagonist. The study aims to understand how this combination can enhance the effectiveness of existing therapies, particularly for patients who cannot tolerate standard chemotherapy. By targeting specific metabolic pathways and survival proteins in AML cells, the research seeks to improve patient outcomes and reduce relapse rates. Patients may be involved in trials assessing the safety and efficacy of this novel treatment strategy.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with acute myeloid leukemia, potentially improving survival rates and reducing the likelihood of relapse.
How similar studies have gone: Previous research has shown promising results with similar approaches targeting metabolic pathways in cancer treatment, indicating potential for success in this novel combination.
Where this research is happening
-
University of Virginia
Charlottesville, United States Active
Researchers
- Principal investigator: Ung, Johnson — University of Virginia
- Study coordinator: Ung, Johnson
Related research
Other NIH-funded projects on the same topics.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant
This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.
-
Targeting the protein housekeeping system in adult leukemia
Researchers are testing a new approach to treat acute myeloid leukemia by disrupting how AML cells manage their proteins, with the goal of helping patients live longer and healthier lives.
-
Understanding how epigenetic helper proteins drive AML and how to target them
A scientist team is studying how accessory proteins in gene-regulating complexes affect acute myeloid leukemia and whether they can be targeted for safer, more precise therapies.
-
Targeting FLVCR1-enabled choline use in a aggressive AML subtype
A new approach aims to block how a specific leukemia subtype (CG-AML) takes up choline to feed its growth, potentially slowing or stopping the disease.
-
Advancing CD70-targeted CAR-NK Therapy for AML
A patient-focused look at a new cell therapy that uses engineered NK cells to target AML by hitting CD70, aiming to reduce relapse with potentially fewer blood cell problems.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.